phrykt

CG Oncology, Inc. (CGON): who owns it and who trades it

As of Nov 16, 2026, CGON insiders reported 17 open-market sales worth $4.8M and 1 purchase worth $24.8M in the last 12 months, with 4% of the sale value made under pre-set 10b5-1 plans. The largest seller was James Mulay (Director), with $3.8M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling CG Oncology

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CGON

226 funds and institutions reported CGON shares worth $6.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Rtw Investments, LP with 10.1%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Rtw Investments, LP10.1%
T. Rowe Price Investment Management, Inc.7.8%
Decheng Capital LLC7.5%
BlackRock, Inc.7.4%
Wellington Management Group LLP6.3%
FMR LLC (Fidelity)4.9%
T. Rowe Price Associates4.5%
TCG Crossover Management, LLC4.3%
Vanguard Portfolio Management LLC4.1%
State Street Corp4.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Rtw Investments, LP8.51M10.08%$605M+22%
T. Rowe Price Investment Management, Inc.6.62M7.84%$470M-2%
Decheng Capital LLC6.37M7.55%$453MNo change
BlackRock, Inc.6.26M7.41%$445M+24%
Wellington Management Group LLP5.32M6.31%$378M-1%
FMR LLC (Fidelity)4.16M4.93%$296M+11%
T. Rowe Price Associates3.81M4.51%$270M+4%
TCG Crossover Management, LLC3.67M4.35%$261MNo change
Vanguard Portfolio Management LLC3.47M4.10%$246M+12%
State Street Corp3.44M4.07%$244M+30%
Vanguard Capital Management LLC3.32M3.93%$236M+9%
Foresite Capital Management VI LLC2.37M2.81%$168M+7%
Geode Capital Management, LLC2.15M2.55%$153M+35%
Seven Fleet Capital Management LP1.89M2.23%$134M+2390%
EcoR1 Capital, LLC1.49M1.77%$106M+36%
DV Trading LLC1.44M1.70%$102MNo change
Avidity Partners Management LP1.40M1.66%$99.4M+9%
Alliancebernstein L.P.1.37M1.63%$93M+7%
Franklin Resources Inc1.31M1.55%$93.3M-13%
Morgan Stanley1.18M1.39%$83.6M+126%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CGON insiders reported $24.8M of open-market purchases and $4.8M of sales. 4% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$24.8M
1 trades, 1 people
Sales, 12 months
$4.8M
17 trades, 2 people
Sales under a 10b5-1 plan
4%
Share of sale value
Latest trade
Oct 15, 2026
Filed Oct 19, 2026

Purchases and sales by month

$24.8M$24.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 15, 2026Leonard E PostDirectorSale plan500$61.65$30.8KForm 4
Oct 15, 2026Leonard E PostDirectorSale plan500$62.48$31.2KForm 4
Sep 15, 2026Leonard E PostDirectorSale1,000$72.98$73KForm 4
Aug 14, 2026Leonard E PostDirectorSale1,000$74.54$74.5KForm 4
Jul 15, 2026Leonard E PostDirectorSale1,000$71.17$71.2KForm 4
Jul 10, 2026James MulayDirectorSale24,165$75.16$1.8MForm 4
Jun 25, 2026Brian Guan-Chyun LiuDirectorPurchase371,085$66.87$24.8MForm 4
Jun 24, 2026Leonard E PostDirectorSale5,000$70.00$350KForm 4
Jun 22, 2026Leonard E PostDirectorSale5,000$65.00$325KForm 4
Jun 15, 2026James MulayDirectorSale plan1,310$60.12$78.8KForm 4
Jun 15, 2026James MulayDirectorSale plan654$60.12$39.3KForm 4
Jun 4, 2026Leonard E PostDirectorSale1,000$54.50$54.5KForm 4
Apr 17, 2026James MulayDirectorSale15,600$73.01$1.1MForm 4
Mar 16, 2026James MulayDirectorSale654$63.50$41.5KForm 4
Mar 16, 2026James MulayDirectorSale1,310$63.50$83.2KForm 4
Jan 9, 2026James MulayDirectorSale10,491$52.99$556KForm 4
Jan 9, 2026James MulayDirectorSale654$44.16$28.9KForm 4
Nov 17, 2025Leonard E PostDirectorSale1,000$41.43$41.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Brian Guan-Chyun LiuDirector$24.8M–Jun 25, 2026
James MulayDirector–$3.8MJul 10, 2026
Leonard E PostDirector–$1.1MOct 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CGON short interest

High short interest. 10.4% of CGON shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short barely changed.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.22M CGON shares were sold short, 10.4% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 840,614 shares, buying them all back would take about 11.0 trading days (days to cover).

Shares short, % of all shares

10.4%May 15Oct 3015.0%

Days to cover

11.0May 15Oct 3018.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.22M10.40%+4%840,61411.0
Oct 15, 20268.87M10.01%-15%919,3799.7
Sep 30, 202610.44M11.78%-7%1.23M8.5
Sep 15, 202611.25M12.70%-1%661,52817.0
Aug 31, 202611.40M12.86%+1%709,06316.1
Aug 14, 202611.25M12.69%-5%757,56214.8
Jul 31, 202611.84M14.03%-2%875,54713.5
Jul 15, 202612.11M14.34%+0%989,35412.2
Jun 30, 202612.07M14.29%+14%1.59M7.6
Jun 15, 202610.56M12.51%+8%909,47211.6
May 29, 20269.81M11.62%+7%966,55210.2
May 15, 20269.18M10.87%-0%917,95510.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

CG Oncology company events

CG Oncology filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 6, 2026.

  1. Nov 6, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026AnnouncementThe Company filed Amendment No. 2 to Prospectus with the Securities and Exchange Commission for the offer and sale of shares of its common stock, par value $0.0001 per share, pursuant to that certain Open Market Sale Agreement, dated March 28, 2025, by and between the Company and Jefferies LLC, to… Filing
  3. Jun 8, 2026VoteReported shareholder vote results. Filing
  4. May 26, 2026LeadershipCG Oncology, Inc. and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026. Filing
  5. May 8, 2026ResultsReleased financial results. Filing
  6. Apr 13, 2026LeadershipCG Oncology, Inc. appointed Jim DeTore as the Company’s Chief Financial Officer. Filing
  7. Feb 27, 2026ResultsReleased financial results. Filing
  8. Jan 13, 2026AnnouncementCG Oncology, Inc. filed Amendment No. 1 to Prospectus with the Securities and Exchange Commission for the offer and sale of shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $550 million, pursuant to that certain Open Market Sale Agreement, dated… Filing
  9. Jan 9, 2026AnnouncementThe Company announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder… Filing
  10. Nov 26, 2025LeadershipThe Board of Directors of CG Oncology, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Christina Rossi to the Company’s Board, effective November 24, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

CG Oncology financials

Famous investors that hold CGON

3 of the 50 well-known investors we track reported holding CGON in their latest 13F filing. The largest position is Ken Fisher's, worth $33.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 2026476,917$33.8M0.0%+4%
Ken Griffin · Citadel AdvisorsQ3 202663,440$4.5M0.0%New
Israel Englander · Millennium ManagementQ3 20264,524$321K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about CG Oncology, Inc. (CGON) stock

Who owns the most CGON stock?

The largest reported owner of CG Oncology, Inc. (CGON) is Rtw Investments, LP, with 10.1% of the company. In total, 226 funds and institutions reported holding CGON at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are CGON insiders buying or selling?

In the last 12 months, CGON insiders reported 1 open-market purchase worth $24.8M and 17 sales worth $4.8M. The latest trade was on Oct 15, 2026. See every trade.

What is the short interest in CGON?

As of Oct 30, 2026, 9.22M CGON shares were sold short, 10.4% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 840,614 shares, buying them all back would take about 11.0 trading days (days to cover). See the history.

Which famous investors hold CGON?

3 of the 50 well-known investors we track reported CGON in their latest 13F filing, including Ken Fisher, Ken Griffin, Israel Englander. The largest position is worth $33.8M. See all holders.

Executive pay

CG Oncology's chief executive was paid a total of $11.9M for the year ended Dec 31, 2025, up 7% from $11.2M the year before. In the last 12 months, CG Oncology's executives and directors bought $24.8M of stock on the open market and sold $4.8M.

Chief executive, total pay$11.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$28.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.